H Lundbeck is collaborating with IBM's Watson Health. It was reported that the collaboration is aimed at accelerating the development of new medicines intended for the treatment of psychiatric and neurological disorders. It will integrate Lundbeck's expertise in the treatment of psychiatric and neurological disorders with IBM's cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments for disorders such as schizophrenia and Parkinson's disease. This partnership is intended to help Lundbeck to set up an innovative approach and new platform for real world evidence and advanced analytics where Lundbeck can take advantage of Watson technology across clinical data from millions of anonymised patient lives made available through the Watson Health Cloud. The platform will allow Lundbeck to use the Watson technologies across additional Lundbeck data and claims data that will be provided through this partnership and made available in the Watson Health Cloud. Lundbeck will also leverage IBM Watson for drug discovery to take advantage of a knowledge-driven approach and in support of the identification of potential new drug targets and alternative drug indications to accelerate discovery and advance the development of therapies.